1.78 USD
▲+0.04+2.59%
盘后 1.72 -0.86%
2026-08-03
市值
$102.00M
市盈率
—
EPS
-0.76
股息率
—
52 周区间
1.60 – 4.94
成交量
917.20K
Beta
3.25
目标价
9.86
52W 低 1.6052W 高 4.94
价格走势
公司简介
Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company’s lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey...